Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Cardiology
ESPS Manuscript NO: 8411
Title: Anti-hypertensive drugs in children and adolescents: Major clinical trials completed for pediatric labeling
Reviewer code: 00186017
Science editor: Gou, Su-Xin
Date sent for review: 2013-12-28 16:31
Date reviewed: 2014-01-05 12:47

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[Y] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[Y] Accept
[ ] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	[ ]Rejection
[ ] Grade D (Fair)	[ ] Grade D: rejected	BPG Search:	[ ] Minor revision
[ ] Grade E (Poor)		[ ] Existed	[ ] Major revision
		[ ] No records	

COMMENTS TO AUTHORS
In this excellent review, authors summarizes the available data and experience supporting the use of antihypertensive drugs in children and adolescents diagnosed with essential hypertension with a particular focus on recent pediatric clinical trials. I have only minor comments: Please, add, in the Abstract and Introduction section, the sources of research as well as the key words that were used. Adding a column on Table 1 with the main side effects of the anti-hypertensive drugs should be of interest.

Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Cardiology
ESPS Manuscript NO: 8411
Title: Anti-hypertensive drugs in children and adolescents: Major clinical trials completed for pediatric labeling
Reviewer code: 00227683
Science editor: Gou, Su-Xin
Date sent for review: 2013-12-28 16:31
Date reviewed: 2014-01-06 09:27

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[ ] Accept
[Y] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	[ ]Rejection
[ ] Grade D (Fair)	[ ] Grade D: rejected	BPG Search:	[Y] Minor revision
[ ] Grade E (Poor)		[ ] Existed	[ ] Major revision
		[ ] No records	

COMMENTS TO AUTHORS
The paper reviews anti-hypertensive drugs in children and adolescents, including drugs for pediatric use approved by the US FDA according to findings of rigorous clinical trials in pediatric patient populations and less well studied but commonly used "older" pediatric antihypertensive drugs. Thus, subtitle "Major clinical trials completed for pediatric labeling" seems to be inaccurate and unnecessary due to the contents reviewed. For a long time, pediatricians have used "off-label" drugs to treat pediatric hypertension. This review can make pediatric cardiologists' practice more evidence-based. The text should be concise. On the contrary, trial design, definition of pediatric hypertension, standards of inclusion and exclusion, endpoints, adverse events, discontinuation of drug use in pediatric clinical trials may be shown in table 2. In addition, can authors extract the special point of anti-hypertensive drugs use in children different from adults according to findings from these pediatric clinical trials?